Empagliflozin protects the heart against ischemia/reperfusion-induced sudden cardiac death
出版年份 2021 全文链接
标题
Empagliflozin protects the heart against ischemia/reperfusion-induced sudden cardiac death
作者
关键词
-
出版物
Cardiovascular Diabetology
Volume 20, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2021-10-05
DOI
10.1186/s12933-021-01392-6
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: A meta-analysis of 34 randomized controlled trials
- (2021) Gilson C. Fernandes et al. HEART RHYTHM
- Mechanistic Insights of Empagliflozin in Nondiabetic Patients With HFrEF
- (2021) Juan Antonio Requena-Ibáñez et al. JACC-Heart Failure
- Load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction
- (2020) Kim A. Connelly et al. Cardiovascular Diabetology
- Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat
- (2020) Sin-Hee Park et al. Cardiovascular Diabetology
- Empagliflozin prevents doxorubicin-induced myocardial dysfunction
- (2020) Jolanda Sabatino et al. Cardiovascular Diabetology
- Comparative efficacy of empagliflozin and drugs of baseline therapy in post-infarct heart failure in normoglycemic rats
- (2020) Marina Krasnova et al. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
- Acute dapagliflozin administration exerts cardioprotective effects in rats with cardiac ischemia/reperfusion injury
- (2020) Sarayut Lahnwong et al. Cardiovascular Diabetology
- SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials
- (2020) Faiez Zannad et al. LANCET
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
- (2020) Milton Packer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
- (2020) Christopher P. Cannon et al. NEW ENGLAND JOURNAL OF MEDICINE
- The sodium–glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats
- (2019) Hsiang-Chun Lee et al. Cardiovascular Diabetology
- Sodium–glucose co‐transporter 2 inhibition with empagliflozin improves cardiac function in non‐diabetic rats with left ventricular dysfunction after myocardial infarction
- (2019) Salva R. Yurista et al. EUROPEAN JOURNAL OF HEART FAILURE
- Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics
- (2019) Carlos G. Santos-Gallego et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet/streptozotocin-induced diabetic rats
- (2019) Qingmiao Shao et al. Cardiovascular Diabetology
- Empagliflozin attenuates ischemia and reperfusion injury through LKB1/AMPK signaling pathway
- (2019) Qingguo Lu et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)–TIMI 58 Trial
- (2018) Stephen D. Wiviott et al. AMERICAN HEART JOURNAL
- Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017
- (2018) Thomas R. Einarson et al. Cardiovascular Diabetology
- Improvement in Cardiovascular Outcomes With Empagliflozin Is Independent of Glycemic Control
- (2018) Silvio E. Inzucchi et al. CIRCULATION
- Type 2 diabetes
- (2017) Sudesna Chatterjee et al. LANCET
- Ischemia/Reperfusion Injury following Acute Myocardial Infarction: A Critical Issue for Clinicians and Forensic Pathologists
- (2017) Margherita Neri et al. MEDIATORS OF INFLAMMATION
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mortality of Myocardial Infarction by Sex, Age, and Obstructive Coronary Artery Disease Status in the ACTION Registry–GWTG (Acute Coronary Treatment and Intervention Outcomes Network Registry–Get With the Guidelines)
- (2017) Nathaniel R. Smilowitz et al. Circulation-Cardiovascular Quality and Outcomes
- Remote Liver Ischemic Preconditioning Protects against Sudden Cardiac Death via an ERK/GSK-3β-Dependent Mechanism
- (2016) Zhaoyang Hu et al. PLoS One
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Reperfusion Injury Salvage Kinase and Survivor Activating Factor Enhancement Prosurvival Signaling Pathways in Ischemic Postconditioning: Two Sides of the Same Coin
- (2010) Derek J. Hausenloy et al. ANTIOXIDANTS & REDOX SIGNALING
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now